Neurogene Business Summary

Neurogene Inc. (NGNE) is a clinical-stage biotechnology company that generates value through the development of genetic medicines for rare, devastating neurological disorders. While the company currently operates as a pre-revenue R&D entity funded primarily through equity financing and private placements, its long-term revenue model is predicated on the commercialization and potential licensing of its proprietary EXACT™ (Exhaustively Augmented Co-expression Technology) transgene regulation platform. This technology is designed to deliver therapeutic levels of a gene while preventing the toxicities associated with overexpression—a common failure point in conventional gene therapy. Its primary business segment is its clinical pipeline, led by NGN-401, an AAV9 gene therapy currently in the Embolden™ registrational trial for Rett syndrome. Following the discontinuation of its CLN5 Batten disease program in late 2024, Neurogene has consolidated its resources toward NGN-401, aiming for a Biologics License Application (BLA) submission supported by its internal cGMP manufacturing facility in Houston. Direct competitors include Taysha Gene Therapies, which is advancing the TSHA-102 program for Rett syndrome, as well as BridgeBio and Spark Therapeutics; Neurogene differentiates itself by utilizing full-length gene delivery coupled with its EXACT™ regulation technology to optimize safety and efficacy. The company was founded in 2018 by Dr. Rachel L. McMinn, Ph.D., who serves as Chief Executive Officer and Executive Chair, bringing a pedigree as a top-ranked biotech analyst and former Chief Business and Strategy Officer at Intercept Pharmaceuticals. The leadership team includes President and CFO Christine Mikail Cvijic, J.D., previously of NPS Pharma and Dendreon, and Chief Scientific Officer Dr. Stuart Cobb, Ph.D., a leading expert in Rett syndrome research. Clinical development is overseen by Chief Medical Officer Dr. Julie Jordan, M.D., while Ricardo Jimenez serves as Senior Vice President of Technical Operations. Neurogene is backed by a sophisticated roster of institutional investors, including Samsara BioCapital, EcoR1 Capital, Redmile Group, RTW Investments, and Casdin Capital. The Board of Directors features notable industry veterans such as Dr. Robert Baffi, a Venture Partner at Samsara and former BioMarin executive, and Rohan Palekar, CEO of 89bio.